Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases

Clinical and Experimental Immunology

Volumn 173, Issue 1, 2013, Pages 112-120

  Frauenknecht, V ^a   Thiel, S ^c   Storm, L ^c   Meier, N ^a   Arnold, M ^a   Schmid, J P ^b   Saner, H ^b   Schroeder, V ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Complement system; Coronary heart disease; Ischaemic stroke; MAp44; MASP

Indexed keywords

FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 1; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 2; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 3; MANNAN-BINDING LECTIN ASSOCIATED PROTEIN MAP44; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMPLEMENT ACTIVATION; COMPLEMENT LECTIN PATHWAY; COMPLEMENT SYSTEM; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; HEART EJECTION FRACTION; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; HYPERTENSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OBESITY; PILOT STUDY; PRIORITY JOURNAL; SMOKING; STROKE PATIENT;

ACUTE DISEASE; AGED; BRAIN ISCHEMIA; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; CORONARY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIAS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; MALE; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; MIDDLE AGED; MYOCARDIAL INFARCTION; OVERWEIGHT; PILOT PROJECTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 84878797556     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12093     Document Type: Article

References (48)

1. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis. J Am Coll Cardiol 2009; 54:2129-2138.
2. Carter AM. Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res 2005; 2:113-121.
3. Oksjoki R, Kovanen PT, Meri S etal. Function and regulation of the complement system in cardiovascular diseases. Front Biosci 2007; 12:4696-4708.
4. Speidl WS, Kastl SP, Huber K etal. Complement in atherosclerosis: friend or foe? J Thromb Haemost 2011; 9:428-440.
5. Frauenknecht V, Schroeder V. Complement-a phylogenetically old system as a new player in the development of atherosclerosis [in German]. Hämostaseologie 2012; 32:276-285.
6. Banz Y, Rieben R. Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann Med 2012; 44:205-217.
7. Markiewski MM, Nilsson B, Nilsson Ekdahl K etal. Complement and coagulation: strangers or partners in crime? Trends Immunol 2007; 28:184-192.
8. Amara U, Flierl MA, Rittirsch D etal. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185:5628-5636.
9. Ricklin D, Hajishengallis G, Yang K etal. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785-797.
10. Hansen S, Selman L, Palaniyar N etal. Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma collectin with microbial-binding activity. J Immunol 2010; 185:6096-6104.
11. Yongqing T, Drentin N, Duncan RC etal. Mannose-binding lectin serine proteases and associated proteins of the lectin pathway of complement: two genes, five proteins and many functions? Biochim Biophys Acta 2012; 1824:253-262.
12. Degn SE, Jensenius JC, Thiel S. Disease-causing mutations in genes of the complement system. Am J Hum Genet 2011; 88:689-705.
13. Kidmose RT, Laursen NS, Dobó J etal. Structural basis for activation of the complement system by C4 cleavage. Proc Natl Acad Sci USA 2012; 109:15425-15430.
14. Degn SE, Jensen L, Hansen AG etal. Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function. J Immunol 2012; 189:3957-3969.
15. Héja D, Kocsis A, Dobó J etal. Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. Proc Natl Acad Sci USA 2012; 109:10498-10503.
16. Sirmaci A, Walsh T, Akay H etal. MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory findings of Carnevale, Malpuech, OSA, and Michels syndromes. Am J Hum Genet 2010; 87:679-686.
17. Rooryck C, Diaz-Font A, Osborn DP etal. Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome. Nat Genet 2011; 43:197-203.
18. Skjoedt MO, Palarasah Y, Munthe-Fog L etal. MBL-associated serine protease-3 circulates in high serum concentrations predominantly in complex with ficolin-3 and regulates ficolin-3 mediated complement activation. Immunobiology 2010; 215:921-931.
19. Dahl MR, Thiel S, Matsushita M etal. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 2001; 15:127-135.
20. Iwaki D, Kanno K, Takahashi M etal. The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway. J Immunol 2011; 187:3751-3758.
21. Degn SE, Hansen AG, Steffensen R etal. MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J Immunol 2009; 183:7371-7378.
22. Skjoedt MO, Roversi P, Hummelshøj T etal. Crystal structure and functional characterization of the complement regulator mannose-binding lectin (MBL)/ficolin-associated protein-1 (MAP-1). J Biol Chem 2012; 287:32913-32921.
23. Pavlov VI, Skjoedt MO, Tan YS etal. Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis. Circulation 2012; 126:2227-2235.
24. Hajela K, Kojima M, Ambrus G etal. The biological functions of MBL-associated serine proteases (MASPs). Immunobiology 2002; 205:467-475.
25. Krarup A, Wallis R, Presanis JS etal. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE 2007; 2:e623.
26. Krarup A, Gulla KC, Gál P etal. The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. Biochim Biophys Acta 2008; 1784:1294-1300.
27. Gulla KC, Gupta K, Krarup A etal. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 2010; 129:482-495.
28. Hess K, Ajjan R, Phoenix F etal. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS ONE 2012; 7:e35690.
29. La Bonte LR, Pavlov VI, Tan YS etal. Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J Immunol 2012; 188:885-891.
30. Trendelenburg M, Theroux P, Stebbins A etal. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2010; 31:1181-1187.
31. Osthoff M, Katan M, Fluri F etal. Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. PLoS ONE 2011; 6:e21338.
32. Mellbin LG, Bjerre M, Thiel S etal. Complement activation and prognosis in patients with type 2 diabetes and myocardical infarction. Diabetes Care 2012; 35:911-917.
33. Zhang M, Hou YJ, Cavusoglu E etal. MASP-2 activation is involved in ischemia-related necrotic myocardial injury. Int J Cardiol 2011; http://dx.doi.org/10.1016/j.ijcard.2011.11.032
34. Cervera A, Planas AM, Justicia C etal. Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS ONE 2010; 5:e8433.
35. Schroeder V, Chatterjee T, Mehta H etal. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88:1020-1025.
36. Schroeder V, Ortner E, Mono ML etal. Coagulation factor XIII activation peptide and subunit levels in patients with acute ischemic stroke: a pilot study. Thromb Res 2010; 126:e122-127.
37. Brott T, Adams HP, Olinger CP etal. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20:864-870.
38. Adams HP Jr, Bendixen BH, Kappelle LJ etal. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993; 24:35-41.
39. Degn SE, Jensen L, Gál P etal. Biological variations of MASP-3 and MAp44, two splice products of the MASP1 gene involved in regulation of the complement system. J Immunol Methods 2010; 361:37-50.
40. Thiel S, Jensen L, Degn SE etal. Mannan-binding lectin (MBL)-associated serine protease-1 (MASP-1), a serine protease associated with humoral pattern-recognition molecules: normal and acute-phase levels in serum and stoichiometry of lectin pathway components. Clin Exp Immunol 2012; 169:38-48.
41. Schwaeble WJ, Lynch NJ, Clark JE etal. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 2011; 108:7523-7528.
42. Orsini F, Villa P, Parrella S etal. Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation 2012; 126:1484-1494.
43. Møller-Kristensen M, Jensenius JC, Jensen L etal. Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. J Immunol Methods 2003; 282:159-167.
44. Ytting H, Christensen IJ, Thiel S etal. Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age, gender and physical exercise. Scand J Immunol 2007; 66:458-464.
45. Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly 2002; 132:241-252.
46. Cortesio CL, Jian W. Mannan-binding lectin-associated serine protease 3 cleaves synthetic peptides and insulin-like growth factor-binding protein 5. Arch Biochem Biophys 2006; 449:164-170.
47. Fischer F, Schulte H, Mohan S etal. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease. Clin Endocrinol (Oxf) 2004; 61:595-602.
48. Conti E, Musumeci MB, De Giusti M etal. IGF-1 and atherothrombosis: relevance to pathophysiology and therapy. Clin Sci 2011; 120:377-402.